患有甲状腺功能低下症的成年人接受帕洛佩特里巴拉提德治疗的患者报告结果:PaTH前进试验延长
Mishaela Rubin1, Andrea Palermo2, Tamara Vokes3
1Columbia University, New York, NY, USA.
The Journal of clinical endocrinology and metabolism
|December 9, 2025
概括
副甲状腺激素 (PTH) 替代疗法用palopegteriparatide显著改善了缺甲状腺症患者的症状和生活质量. 这些好处持续了很长一段时间,为管理这种慢性疾病提供了新的希望.
科学领域:
- 内分泌学 在内分泌学.
- 临床药理学 临床药理学
背景情况:
- 低甲状腺功能障碍严重影响患者的身体和认知健康,导致生活质量 (QoL) 降低,尽管传统的治疗.
- 目前的治疗方法 (活性维生素D和) 往往无法完全解决缺甲状腺症的多方面的症状.
研究的目的:
- 评估使用帕洛佩特里帕拉提胺的副甲状腺激素 (PTH) 替代疗法在患有慢性副甲状腺功能障碍的成年人中的长期疗效.
- 评估治疗对疾病特异性症状,日常功能,幸福感和整体体质量生活的影响.
- 探索患者特征与治疗结果之间的关联.
主要方法:
- PaTH Forward试验涉及一个随机的,双盲的,安慰剂控制的阶段,随后是延长的开放标签期,直到266周.
- 患者报告的结果 (PROs) 采集了使用低甲状腺功能障碍患者经验量表 (HPES) 和简短形式健康调查 (SF-36v2) 的结果.
- 用描述性统计和重复测量混合模型 (MMRM) 分析数据.
主要成果:
- 从第12周到第110周,Palopegteriparatide治疗导致疾病特异性症状,日常功能和幸福感的显著持续改善.
- 观察到PRO的临床上有意义的改善,表明对患者的日常生活产生积极影响.
- 通过SF-36v2得分也记录了与一般健康相关的QoL的显著改善,在各种患者人口统计学中取得了一致的结果.
结论:
- 用帕洛佩特里巴拉提提德 (palopegteriparatide) 进行长期副甲状腺激素 (PTH) 替代疗法,在疾病特异性症状和对日常功能和幸福感的影响方面显示出显著和持续的改善.
- 该疗法还导致慢性偏偏甲状腺症的成年人与一般健康相关的QoL显著改善.
- 这些发现支持palopegteriparatide作为一种有价值的治疗选择,用于治疗缺甲状腺症.
相关概念视频
The Parathyroid Glands
4.2K
The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
4.2K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
534
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
534
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
418
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
418
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
426
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
426
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K


